- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06032637
Best Incision in Cesarean Section of Obese Women
Difference Between Pfannenstiel Incision and Higher Transverse Supra Umbilical Incision, During Elective Cesarean Section in Morbidly Obese Patients
The goal of this comparative clinical trial is to compare Pfannenstiel incision and higher transverse supra umbilical incision techniques during elective cesarean section in morbidly obese patients. The main questions it aims to answer are:
Is there a difference in operative time between the two incision techniques? Is there a difference in estimated blood loss between the two techniques? Is there a difference in post-operative pain scores between the two techniques? Is there a difference in wound complication rates between the two techniques? Participants will be randomly assigned to receive either a Pfannenstiel incision or a higher transverse supra umbilical incision during their scheduled cesarean delivery.
Researchers will compare the Pfannenstiel incision group to the higher transverse supra umbilical incision group to see if there are differences in operative time, blood loss, post-operative pain, and wound complications.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This randomized controlled trial will enroll 60 morbidly obese pregnant patients scheduled for elective cesarean delivery at gestational age ≥37 weeks. Morbid obesity will be defined as pre-pregnancy body mass index ≥40 kg/m2.
Patients will be randomly allocated to one of two groups (30 patients per group):
Group 1 (Pfannenstiel group): Patients will undergo a transverse infraumbilical skin incision 2-3 cm above the symphysis pubis, followed by transverse incision of the anterior rectus sheath in the same line as the skin incision, blunt digital separation of the rectus muscles, and transverse uterine incision in the lower segment.
Group 2 (Supra-umbilical transverse group): Patients will undergo a transverse skin incision halfway between the umbilicus and xiphoid process, followed by transverse incision of the anterior rectus sheath in the same line, blunt digital separation of the rectus muscles, and transverse uterine incision in the lower segment.
The primary outcome measures will be operative time, estimated blood loss, post-operative pain scores, and wound complication rates. Secondary outcomes will include length of hospital stay, patient satisfaction scores, and cosmetic results.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Muhamed Alhagrasy, M.D.
- Phone Number: 01017313413
- Email: MuhamedAhmed.216@azhar.edu.eg
Study Locations
-
-
-
Cairo, Egypt, 11633
- Al-Hussein University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Female patients aged between 20 and 40 years.
- Singleton pregnancy.
- Gestational age ≥ 37 weeks.
- Scheduled for elective cesarean delivery.
- Morbid obesity, defined as pre-pregnancy body mass index (BMI) ≥ 40 kg/m2.
- Willing and able to provide informed consent.
- Able to adhere to study procedures and follow-up schedule.
Exclusion Criteria:
- Emergency cesarean delivery.
- Multiple gestation (twins, triplets, etc)
- Placenta previa or vasa previa.
- History of more than 1 previous cesarean delivery.
- HIV, hepatitis B/C infection.
- Current anticoagulation therapy.
- Immune-compromised conditions.
- Premature rupture of membranes.
- Pre-existing skin conditions affecting the abdomen.
- Inability to provide informed consent.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Pfannenstiel incision
Patients randomized to the Pfannenstiel incision arm will undergo a transverse skin incision 2-3cm above the symphysis pubis.
Subcutaneous tissue will be dissected until anterior rectus sheath is exposed.
A transverse incision will be made through the rectus sheath in line with the skin incision, avoiding injury to the inferior epigastric arteries.
Rectus muscles will be separated manually along midline using blunt dissection.
The peritoneum will be incised transversely and the hysterotomy extended laterally with uterine traction to deliver fetus.
The visceral peritoneum will not be closed.
Rectus muscles will not be re-approximated.
Subcutaneous tissue will not be irrigated.
Subcutaneous tissue will be closed if over 2cm depth.
Skin will be closed with non-absorbable suture subcuticularly.
|
Patients randomized to the supra-umbilical transverse incision arm will receive a transverse skin incision halfway between the umbilicus and xiphoid process, extending laterally to the semilunar lines.
The subcutaneous tissue will be bluntly dissected until the anterior rectus sheath is exposed.
A transverse incision will be made through the rectus sheath in line with the skin incision, avoiding injury to the superior epigastric vessels.
The rectus muscles will be split manually using blunt dissection.
The peritoneum will be incised transversely and the hysterotomy extended laterally to deliver the fetus.
The visceral peritoneum will not be closed.
The rectus muscles will not be re-approximated.
The subcutaneous tissue will not be irrigated but closed if over 2cm depth.
The skin will be closed with non-absorbable suture subcuticularly.
|
Experimental: Supra-Umbilical
Patients randomized to the supra-umbilical transverse incision arm will undergo a transverse skin incision halfway between the umbilicus and xiphoid process, extending laterally to the semilunar lines.
Subcutaneous tissue will be bluntly dissected until anterior rectus sheath is exposed.
A transverse incision will be made through the rectus sheath in line with the skin incision, avoiding injury to the superior epigastric vessels.
Rectus muscles will be split manually along midline using blunt dissection.
The peritoneum will be incised transversely and the hysterotomy extended laterally with uterine traction to deliver fetus.
The visceral peritoneum will not be closed.
Rectus muscles will not be re-approximated.
Subcutaneous tissue will not be irrigated.
Subcutaneous tissue will be closed if over 2cm depth.
Skin will be closed with non-absorbable suture subcuticularly.
|
Patients randomized to the supra-umbilical transverse incision arm will receive a transverse skin incision 3-4cm above the umbilicus, extending laterally to the semilunar lines, without panniculus retraction.
The subcutaneous tissue will be bluntly dissected until the anterior rectus sheath is exposed.
The rectus sheath will be incised transversely using electrocautery for hemostasis, avoiding injury to the superior epigastric vessels.
The rectus muscles will be split manually along the midline using blunt dissection.
The peritoneum will be transversely incised and the hysterotomy extended laterally to deliver the fetus.
The visceral peritoneum will not be closed.
The rectus muscles will not be re-approximated.
The subcutaneous tissue will not be irrigated but closed if over 2cm depth.
The skin will be closed with non-absorbable suture subcuticularly.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of surgical site wound infection
Time Frame: 4 weeks after the surgery.
|
Surgical site infections will be assessed at the cesarean incision site and tracked for 4 weeks postoperatively.
Wound infection will be defined as purulent drainage from the incision, positive culture, and/or at least two of the following signs or symptoms: pain or tenderness, localized swelling, redness, or heat.
The 4-week timeframe starts on the day of surgery (day 0) and ends 28 days postoperatively.
Wound infections occurring up to 4 weeks after surgery will be captured and recorded as the primary outcome measure.
Wound assessments will be performed daily during the hospital stay, at the post-op visit around 2 weeks, and at the 4-week follow-up visit.
|
4 weeks after the surgery.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Operative time
Time Frame: during the surgery
|
Operative time will be defined as the time from skin incision to complete wound closure.
It will be recorded in minutes by a study investigator observing each procedure.
|
during the surgery
|
Hospital length of stay
Time Frame: From day of surgery to discharge, up to 8 weeks.
|
Hospital length of stay will be defined as the number of days from surgery until discharge from the hospital.
|
From day of surgery to discharge, up to 8 weeks.
|
Estimated blood loss
Time Frame: during the procedure
|
Estimated blood loss will be assessed by the anesthesiologist and surgeon at the end of the procedure, based on the amount of blood in the suction canister and blood-soaked sponges/lap pads.
|
during the procedure
|
Postoperative pain
Time Frame: From end of surgery through 4 weeks postoperatively
|
Postoperative pain will be assessed using a visual analog scale (VAS) of 0-10, with 0 being no pain and 10 being worst possible pain.
Patients will rate their pain level at set intervals after surgery - immediately after recovery room discharge, daily while inpatient, and at 2 weeks and 4 weeks postop during follow-up visits.
|
From end of surgery through 4 weeks postoperatively
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Muhamed A Alhagrasy, M.D., Al-Azhar University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Obstet1222
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
The study involves a vulnerable population of pregnant women and collecting sensitive health information. Sharing individual participant data could risk participant privacy and confidentiality even if de-identified.
The sample size is small at only 60 participants. individual participant data from such a small sample has a higher risk of re-identification.
The research team intends to use the individual participant data for additional analyses and future studies. Sharing individual participant data may lead to misuse, misinterpretation, or compromised validity if not properly analyzed.
Logistical barriers make preparing and curating a database for individual participant data sharing highly resource and time intensive for the research team.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cesarean Section Complications
-
Assiut UniversityNot yet recruitingCesarean Section Complications | Cesarean Section Niche
-
Recep Tayyip Erdogan University Training and Research...CompletedCesarean Section Complications | Cesarean Section; DehiscenceTurkey
-
Atatürk UniversityUnknownCesarean Section Complications | Cesarean Section; Complications, Wound, Dehiscence | Cesarean Section, Repeated | Cesarean, Uterine Scar Thickness | Cesarean, Residual Myometrial ThicknessTurkey
-
University of CalgaryNot yet recruitingCesarean Section ComplicationsCanada
-
Peking University People's HospitalNot yet recruiting
-
Aswan University HospitalCompletedCesarean Section ComplicationsEgypt
-
Gaziosmanpasa Research and Education HospitalUnknownCesarean Section ComplicationsTurkey
-
Ain Shams UniversityUnknownCesarean Section ComplicationsEgypt
-
Mohamed Abdelrady MohamedCompletedCesarean Section ComplicationsEgypt
-
McGill University Health Centre/Research Institute...Thammasat UniversityUnknownCesarean Section ComplicationsCanada
Clinical Trials on Pfannenstiel incision
-
University Hospital HeidelbergUnknownDonor NephrectomyGermany
-
Ain Shams Maternity HospitalRecruitingCesarean Section ComplicationsEgypt
-
The University of Texas Health Science Center,...The University of Texas Medical Branch, GalvestonCompleted
-
Ain Shams UniversityCompleted
-
Sunnybrook Health Sciences CentreNot yet recruitingPregnancy Related | Cesarean Section | Post-operative Pain | Fascial Closure | Surgical Technique
-
Near East University, TurkeyCompletedCesarean Delivery Affecting Fetus | Incision, Surgical | Pfannenstiel Incision Length | Fetal Occipitofrontal DiameterTurkey
-
Universidade do Vale do SapucaiCompleted
-
Sahlgrenska University Hospital, SwedenThe Swedish Society of Medicine; The Swedish agreement concerning research...CompletedColorectal Neoplasm | Diverticulitis | ColostomySweden
-
Hospital Universitario Ramon y CajalCompletedCataract | Astigmatism | Refractive SurgerySpain
-
Université de SherbrookeCompletedSurgical Wound | Patient Satisfaction | General Surgery | IncisionCanada